ArticleApplied health economics and health policy2021
Budget Impact of Microbial Cell-Free DNA Testing Using the Karius
Article in Applied health economics and health policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 35 citations in OpenAlex.
- Rapid Microbiological Diagnostics for Sepsis: Narrative Review of Current and Prospective Approaches.Critical care explorations · 2026Review
- Advances in the Diagnosis of Invasive Pulmonary Mold Infections: Focus on Diagnostic Performance and Cost-Effectiveness of Diagnostic Tests.Diagnostics (Basel, Switzerland) · 2026Review
- From Culture-Negative to DNA-Positive: The Molecular Revolution in Infective Endocarditis Diagnosis.Pathogens (Basel, Switzerland) · 2025Review
- From Chart Biopsy to Liquid Biopsy: Evaluating the Diagnostic Yield and Clinical Impact of Plasma Microbial Cell-Free DNA Next-Generation Sequencing in the Management of Fever of Unknown Origin.Open forum infectious diseases · 2025Article
- Yield of clinical metagenomics: insights from real-world practice for tissue infections.EBioMedicine · 2025Article
- Use of Cell-Free DNA Testing to Diagnose Infective Endocarditis in a Patient With Negative Blood Cultures.Cureus · 2024Article
- Plasma Microbial Cell-free DNA Next-generation Sequencing Can Be a Useful Diagnostic Tool in Patients With Osteoarticular Infections.Open forum infectious diseases · 2024Article
- Status check: next-generation sequencing for infectious-disease diagnostics.The Journal of clinical investigation · 2024Article
- Circulating Microbial Cell-Free DNA in Health and Disease.International journal of molecular sciences · 2023Review
- Unusual Presentation of DisseminatedTransplantation direct · 2022Article
- Stewardship of Molecular Diagnostics in Transplant Viral Infections.Transplant infectious disease : an official journal of the Transplantation SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive fungal infection is a major source of morbidity and mortality. The usage of microbial cell-free DNA for the detection and identification of invasive fungal infection has been considered as a potential alternative to invasive procedures allowing for rapid results.
objectiveThis analysis aimed to assess the budget implications of using the Karius
methodsThe analysis used a decision tree to capture key stages of the patient pathway, from suspected invasive fungal infection to either receiving treatment for invasive fungal infection or being confirmed as having no invasive fungal infection. The analysis used published costs and resource use from a targeted review of the literature. Because of the paucity of published evidence on the reduction of diagnostic tests displaced by the Karius Test, the analysis used a 50% reduction in the use of bronchoscopy and/or bronchoalveolar lavage. The impact of this reduction was tested in a scenario analysis.
resultsThe results of the analysis show that the introduction of the Karius Test is associated with a cost saving of US$2277 per patient; when multiplied by the estimated number of cases per year, the cost saving is US$17,039,666. The scenario analysis showed that the Karius Test only had an incremental cost of US$87 per patient when there was no reduction in bronchoscopy and bronchoalveolar lavage.
conclusionsThe Karius Test may offer a valuable and timely option for the diagnosis of invasive fungal infection through its non-invasive approach and subsequent cost savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.